What glucagon dose and repeat dosing schedule should be used for severe hypoglycemia, including route and considerations for sulfonylurea therapy?

Glucagon Dosing for Severe Hypoglycemia

For severe hypoglycemia in adults and children weighing ≥44 lbs (20 kg), administer 1 mg glucagon subcutaneously, intramuscularly, or intravenously; for children <44 lbs (20 kg), give 0.5 mg (or 20-30 mcg/kg). If no response occurs within 15 minutes, repeat the same dose while awaiting emergency medical services 1, 2.

Standard Dosing by Weight

Adults and children ≥20 kg (44 lbs):

• Dose: 1 mg glucagon
• Routes: Subcutaneous, intramuscular, or intravenous (all equally effective for non-emergency settings) 2
• Expected response: Blood glucose rise within 5-15 minutes 3

Children <20 kg (44 lbs):

• Dose: 0.5 mg glucagon (or 20-30 mcg/kg) 3, 2
• Alternative pediatric dosing: Some evidence suggests 30 mcg/kg (maximum 1 mg) provides faster response, though 10 mcg/kg causes less nausea with similar 20-minute glucose levels 3

Route Selection

Intravenous administration produces the highest initial plasma glucagon levels and fastest blood glucose rise in the first 5 minutes, making it the preferred route when IV access is available 4. However, subcutaneous and intramuscular routes are equally effective for achieving therapeutic blood glucose recovery, with no clinically significant difference in outcomes 4. The practical reality is that most severe hypoglycemia occurs outside medical facilities, making subcutaneous or intramuscular administration the standard approach.

Repeat Dosing Protocol

If the patient remains unconscious or hypoglycemic after 15 minutes:

• Administer an additional dose of the same amount 1, 2
• Immediately call emergency services after the first dose—do not wait to see if a second dose is needed 1
• The short half-life of glucagon and potential for cerebral hypoglycemia damage make urgent medical evaluation essential 2

Post-Recovery Management

Once the patient awakens and can safely swallow:

• Provide 15-20 g of rapidly absorbed carbohydrate (glucose tablets, fruit juice, regular soft drink) 1
• Follow with a meal or snack containing both protein and carbohydrates (cheese and crackers, peanut butter sandwich) to restore liver glycogen and prevent recurrent hypoglycemia 1, 2
• Position unconscious patients on their side to prevent aspiration if vomiting occurs 2

Newer Glucagon Formulations

The 2022 AACE guidelines emphasize that newer glucagon preparations eliminate reconstitution requirements and may improve real-world administration success 1:

Intranasal glucagon:

• Dose: 3 mg (single-use device) 1
• Achieves comparable glucose recovery to injectable forms 1
• Higher incidence of nasal and ophthalmologic adverse events but easier administration 5

Stable liquid formulations (dasiglucagon, nonaqueous glucagon):

• Dose: 0.6 mg dasiglucagon achieves glucose >70 mg/dL in 6 minutes, comparable to standard 1 mg glucagon 1
• Pre-filled syringes or auto-injectors eliminate preparation steps 1
• May have slightly longer time to recovery (mean difference 2.22 minutes) but similar overall efficacy 5

Special Considerations for Sulfonylurea-Induced Hypoglycemia

Sulfonylurea-induced hypoglycemia requires heightened vigilance because these agents cause prolonged insulin secretion 1, 6. While glucagon remains effective and produces greater, more prolonged blood glucose elevation when given intramuscularly versus intravenously in this context 6, patients require:

• Hospitalization for prolonged observation due to risk of recurrent hypoglycemia 1
• More aggressive carbohydrate replacement after initial recovery 1
• Possible adjustment of sulfonylurea regimen to prevent recurrence 1
• Recognition that certain antibiotics (sulfamethoxazole/trimethoprim, metronidazole) significantly increase hypoglycemia risk when combined with sulfonylureas 7

Critical Prescribing Mandate

Glucagon must be prescribed to all individuals at increased risk of severe hypoglycemia (level 2 or 3), including anyone on insulin therapy or with history of severe hypoglycemia 8, 9, 10. Caregivers, family members, and school personnel should know its location and receive training in administration—healthcare professional status is not required to administer glucagon 8, 11, 9, 10.

Common Pitfalls

• Nausea and vomiting are expected side effects that may also result from the hypoglycemia itself 2
• Glucagon is ineffective when taken orally—it must be injected or administered intranasally 2
• Failure to provide follow-up carbohydrates leads to recurrent hypoglycemia as glucagon's effect wanes 1, 2
• Delaying emergency services while attempting repeated glucagon doses risks permanent neurologic damage 2